NCT07176754

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Not yet recruiting NA Last updated 16 September 2025

What this trial tests

NA trial testing Infliximab in Cardiac Arrest (CA) in 208 participants. Not yet recruiting.

Timeline

1 October 2025

Primary endpoint
31 July 2028

31 October 2028

Quick facts

Lead sponsor	Peking University Third Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	208
Start date	1 October 2025
Primary completion	31 July 2028
Estimated completion	31 October 2028

Drugs / interventions tested

• Infliximab (infliximab) — full drug profile →
• Sodium chloride injection USP, 0.9% (placebo) — full drug profile →

Conditions studied

• Cardiac Arrest (CA) — all drugs for Cardiac Arrest (CA) →
• Post Cardiac Arrest Syndrome — all drugs for Post Cardiac Arrest Syndrome →

Sponsor

Peking University Third Hospital

Who can join

18 and older, any sex, with Cardiac Arrest (CA) or Post Cardiac Arrest Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the role of this treatment in modulating the systemic inflammatory response and its potential impact on 90- and 180-day morbidity and mortality and neurological outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.